As First Patient Is Enrolled in the Clinical Trial of Braive Growth Modulation System, Study Reaffirms Medtronic’s Commitment to Pediatric Spine Innovation
– Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that it has enrolled its first patient and completed the first surgical procedure in its BRAIVE IDE study which will evaluate the safety and effectiveness of the Braive growth modulation system for treatment of progressive Adolescent Idiopathic Scoliosis (AIS). The first patient was recruited by The Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom . The device is Medtronic’s latest innovation in the pediatric spine category, and the study’s initiation reaffirms the company’s commitment to continued innovation for pediatric patients.
About 4% of children globally have scoliosis, making it one of the most common pediatric orthopedic deformities. 1 It occurs when the vertebrae twist or rotate, causing the spine to curve into a “C” or “S” shape, rather than a straight line. It typically occurs in children and impacts girls more often than boys. Standard treatment options may include braces or spinal fusion surgery. According to the National Scoliosis Foundation, an estimated 30,000 children a year receive a brace to treat their condition, while 38,000 patients are treated with spinal fusion. 2 While successful in correcting the spine’s curve, spinal fusion causes vertebrae to fuse together into a single bone, which...
Read Full Story: https://investingnews.com/news/medical-device-investing/medtronic-begins-pediatric-clinical-trial-of-spinal-tether-for-treatment-of-scoliosis/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.